

Continuous glucose monitoring amongst pregnant women with early-onset type 2 diabetes

Submission date 19/10/2023	Recruitment status Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 23/10/2023	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 01/11/2023	Condition category Pregnancy and Childbirth	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Previous studies have shown that Continuous Glucose Monitoring (CGM) improves maternal glucose, reduces neonatal admissions and is clinically and cost-effective in type 1 diabetes (T1D) pregnancy, and as a result CGM is now standard care in T1D pregnancy. However, there are no well-designed adequately powered trials to compare CGM and standard care monitoring of blood glucose in type 2 diabetes (T2D) pregnancy.

The purpose of this study is to examine whether using CGM improves glucose levels in pregnant women with T2D and whether it leads to better outcomes for the baby. We will also look at its impact on maternal wellbeing, diabetes treatment satisfaction, and cost effectiveness.

Who can participate?

We are aiming to recruit 422 pregnant women aged 16 years and above with T2D.

What does the study involve?

Eligible participants will be approached early in pregnancy and if consent is given they will be enrolled. All participants will wear a masked sensor for 7-14 days to collect baseline CGM data. Participants will then be randomly allocated to receive either study CGM or the current standard of care (fingerprick blood glucose monitoring, or continuous glucose monitoring) for the rest of pregnancy.

Study visits are aligned with routine antenatal visits every 4 weeks. A blood sample for metabolic phenotyping will be obtained at the recruitment visit. The participant will be asked to complete questionnaires at the recruitment visit and then again at around 32 weeks' gestation. Blood samples for HbA1c will be taken at baseline, 28-week, 32-week, and 36-week visits. Participants in the control arm will wear a masked sensor for 14 days at 20, 28, 32 and 36 weeks' gestation. Following delivery we will collect information on birth and infant. 20-25 participants will also be interviewed at baseline and around 32-36 weeks' gestation to examine, among other things, barriers and facilitators for CGM use in this population.

What are the possible benefits and risks of participating?

None

Where is the study run from?

University of East Anglia (UK)

When is the study starting and how long is it expected to run for?

May 2023 to April 2027

Who is funding the study?

National Institute for Health and Care Research (NIHR) (UK).

Who is the main contact?

Corinne Collett, C.Collett@uea.ac.uk

protect.trial@uea.ac.uk

Contact information

Type(s)

Scientific, Principal Investigator

Contact name

Prof Helen R Murphy

ORCID ID

<http://orcid.org/0000-0002-5489-0614>

Contact details

Norwich Medical School, Floor 2, Bob Champion Research and Education Building, University of East Anglia, Norwich Research Park

Norwich

United Kingdom

NR4 7UQ

+44 (0)1603 591657

Helen.Murphy@uea.ac.uk

Type(s)

Scientific, Principal Investigator

Contact name

Prof Eleanor Scott

ORCID ID

<http://orcid.org/0000-0001-5395-8261>

Contact details

LICAMM, LIGHT Laboratories, Clarendon Way, University of Leeds

Leeds

United Kingdom

LS2 9JT
+44 (0)113 343 7762
E.M.Scott@leeds.ac.uk

Type(s)

Public

Contact name

Ms Corinne Collett

ORCID ID

<http://orcid.org/0000-0002-5510-1488>

Contact details

Norwich Clinical Trials Unit
Norwich Medical School
University of East Anglia
Norwich
United Kingdom
NR4 7TJ

-

C.Collett@uea.ac.uk

Type(s)

Public

Contact name

Dr Study Team

Contact details

Norwich Clinical Trials Unit
Norwich Medical School
University of East Anglia
Norwich
United Kingdom
NR4 7TJ

-

protect.trial@uea.ac.uk

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

331906

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

CPMS 58352, NIHR150958, IRAS 331906

Study information

Scientific Title

Pregnancy Outcomes using continuous glucose monitoring TEchnology in pregnant women with early-onset Type 2 diabetes: A multicentre randomised controlled trial of the clinical and cost-effectiveness of using continuous glucose monitoring (CGM) in pregnant women with early-onset type 2 diabetes

Acronym

PROTECT

Study objectives

In pregnant women with early-onset type 2 diabetes, the use of real-time CGM is more effective than standard clinical care (finger-prick self-monitoring blood glucose testing, continuous glucose monitoring) for improving the percentage of time spent in the pregnancy target glucose range of 3.5-7.8 mmol/L and reducing clinically relevant neonatal morbidity (neonatal care admission) or perinatal death.

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 19/09/2023, South Central - Berkshire B Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 2071048276; berkshireb.rec@hra.nhs.uk), ref: 23/SC/0315

Study design

Interventional randomized controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Home, Hospital

Study type(s)

Other

Participant information sheet

Health condition(s) or problem(s) studied

Early-onset type 2 diabetes in pregnancy

Interventions

Recruitment visit: When women have expressed their wish to participate, they will be invited for the recruitment visit, when the following activities will be performed by the research team:

- Checking inclusion and exclusion criteria
- Written informed consent
- Baseline socio-demographic data collection
- Relevant medical / obstetric history and present medical (diabetes, comorbidity, medication, and obstetric) information
- Body weight and height, calculation of BMI
- Early pregnancy HbA1c recorded (or performed if not previously done in this pregnancy)
- Blood sample taken for metabolic phenotyping (C-peptide, autoantibodies, genetic risk score)
- Baseline questionnaire pack provided for participants to complete at home (either paper or electronically via link)
- Masked Freestyle Libre 3 sensor insertion (ideally 2 weeks prior to randomisation)

Women will have a small glucose sensor inserted under the skin by the clinical research team and will be instructed to wear it at home for up to 14 days. They will not be able to see the glucose information from this sensor.

Randomisation visit:

Ideally the sensor will be in place for 14 days, however if necessary to meet timelines, at least 3-4 days of CGM data should be available prior to randomisation (prior to 16 weeks' gestation). At the randomisation visit, the following will be performed:

- Masked CGM sensor upload & review (to confirm adequate baseline data available). Those randomised to the intervention arm will have access to the data from the masked sensor period following randomisation.
- Collection / confirmation of completed baseline questionnaires
- Record average total daily dose (TDD) of insulin during the previous 3 days
- Randomisation via study website
- Participant training

Participants in the CGM group will be shown how to apply the sensor, how to understand and use the CGM apps, how to interpret the data to guide decisions on eating and activity, recommended targets, and metformin / insulin dose adjustment.

Participants in the control arm will receive fingerstick self-monitoring blood glucose or continuous glucose monitoring training per local standard of care, along with advice on recommended targets, managing their diabetes in pregnancy, and metformin/insulin dose adjustment if relevant.

Participants will use their allocated glucose monitoring method throughout pregnancy, until after delivery.

Subsequent Study Visits

Follow up visits will be every 4 weeks at ~16/40, 20/40, 24/40, 28/40, 32/40, 36/40. It is expected that study visits will align with routine NHS antenatal clinic visits however virtual study visits will be offered if appropriate.

At these visits the following data will be recorded on the study database:

- Weight
- Blood pressure
- Glucose monitoring method(s), frequency of glucose testing
- Insulin delivery method(s), dose and type
- Adverse events of special interest

In addition, the following will be performed at key visits:

- Masked CGM for control group participants (14 days data collection) at 20, 28, 32, and 36 weeks' gestation

- Blood collection for HbA1c at 28, 32, and 36 weeks' gestation
- Follow-up questionnaires at 32 weeks' gestation

Delivery visit

The following obstetric and neonatal outcomes will be collected:

- Mode of delivery (vaginal, instrumental, elective/emergency caesarean section)
- Gestational age at delivery and indication for any preterm delivery <37 weeks
- Infant(s) birth weight
- Adverse events (pregnancy loss <24 weeks, stillbirth, neonatal death)

Neonatal follow up

Neonatal assessment is at hospital discharge (or 28 days if admission prolonged). The following data will be collected:

- Neonatal morbidity (treatment for neonatal hypoglycaemia, neonatal jaundice, respiratory distress)
- Neonatal care admission (duration of stay at each level of care)
- Infant feeding at hospital discharge
- Neonatal readmission in first 7 days after birth

Questionnaires

Participants will be asked to complete questionnaires at home, electronically or on paper, at baseline and again at 32 weeks:

- T2D Distress Scale (DDS)
- Glucose Monitoring Satisfaction Survey (GMSS)
- Patient Health Questionnaire 9-item depression scale (PHQ-9)
- Generalized Anxiety Disorder 7-item scale (GAD-7)
- EQ-5D

Optional qualitative interviews

20-25 participants will be purposively selected by socio-demographic factors to take part in the semi-structured interviews, in early pregnancy (after randomisation) and again at around 32-36 weeks' gestation. Interviews will take place remotely or in person.

Intervention Type

Device

Pharmaceutical study type(s)

Not Applicable

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Continuous glucose monitoring

Primary outcome measure

1. Percentage time spent with maternal glucose levels within target range as recorded by CGM Time-In-Range (TIR 3.5-7.8mmol/l) from 20 until 38 weeks' gestation or until delivery, if delivery is earlier than 38 weeks' gestation
2. Neonatal unit admission or death (stillbirth/neonatal death) From randomisation to discharge after delivery (or 28 days post delivery if admission prolonged)

Secondary outcome measures

1. HbA1c & CGM mean glucose, GMI, frequency & duration of glycaemic excursions [%Time-Above-Range (≥ 6.7 & ≥ 7.8 mmol/L), %Time-Below-Range (≤ 3.5 & ≤ 3.0 mmol/L)], glycaemic variability (glucose SD, CV)] From 20 until 38 weeks' gestation or until delivery, if delivery is earlier than 38 weeks' gestation
2. Hypertensive disorders from randomisation to discharge after delivery (or 28 days post delivery if admission prolonged)
3. Gestational weight gain from baseline (early pregnancy) to last visit prior to delivery
4. Diabetes treatment (metformin & insulin use) From 20 until 38 weeks' gestation or until delivery, if delivery is earlier than 38 weeks' gestation
5. Hospital admissions & duration of stay from randomisation to discharge after delivery (or 28 days post delivery if admission prolonged)
6. Severe hypoglycaemia, hyperosmolar hyperglycaemic state, and diabetic ketoacidosis episodes from randomisation to discharge after delivery (or 28 days post delivery if admission prolonged)
7. Gestational age at birth
8. Birth weight for gestational age (SDS) (GROW customised birth weight, LGA birth weight >90th centile or SGA <10th centile) at Birth
9. Mode of delivery at delivery
10. Neonatal unit admission >24hrs (duration of stay, highest level care) at Discharge after delivery
11. Adverse events (pregnancy loss <24 weeks, congenital anomaly (any), stillbirth, neonatal death) at Delivery
12. Birth injury (spinal cord injury, clavicular, skull or bone fracture, shoulder dystocia, nerve palsy, subdural or intracerebral haemorrhage, hypoxic ischaemic encephalopathy) at Birth
13. Neonatal morbidity (treatment for neonatal hypoglycaemia, respiratory distress requiring treatment, neonatal jaundice requiring treatment) at Discharge after delivery
14. Feeding at hospital discharge (exclusive breast-feeding / partial breast-feeding / exclusive formula feeding) at Discharge after delivery
15. Diabetes distress, anxiety & depression and treatment satisfaction using short questionnaires at Baseline & 32 weeks' gestation
16. Qualitative study to explore the acceptability, barriers, and facilitators for CGM use in T2D pregnancy at Baseline & 32-36 weeks' gestation
17. Incremental cost per quality-adjusted life year (QALY) at Randomisation to discharge after delivery

Overall study start date

01/05/2023

Completion date

30/04/2027

Eligibility

Key inclusion criteria

1. Type 2 diabetes (T2D)
2. 16 years of age or over
3. Confirmed pregnancy ≤ 14 weeks' gestation

4. HbA1c of ≥ 43 mmol/mol (6.1%) in pregnancy (≤ 14 weeks' gestation)
5. Willingness to use the study devices throughout the trial
6. Able to provide informed consent

Participant type(s)

Patient

Age group

Adult

Lower age limit

16 Years

Sex

Female

Target number of participants

Planned Sample Size: 422; UK Sample Size: 422

Key exclusion criteria

1. Non-type 2 diabetes
2. Chronic kidney disease (CKD) grade 4 or 5 (GFR < 30 ml/min)
3. Severe visual impairment

Date of first enrolment

01/01/2024

Date of final enrolment

28/02/2026

Locations**Countries of recruitment**

England

United Kingdom

Study participating centre

Norfolk and Norwich University Hospitals NHS Foundation Trust

Colney Lane

Colney

Norwich

United Kingdom

NR4 7UY

Study participating centre

Leeds Teaching Hospitals NHS Trust

St. James's University Hospital
Beckett Street
Leeds
United Kingdom
LS9 7TF

Study participating centre**University College London Hospitals NHS Foundation Trust**

250 Euston Road
London
United Kingdom
NW1 2PG

Study participating centre**Calderdale and Huddersfield NHS Foundation Trust**

Trust Headquarters
Acre Street
Lindley
Huddersfield
United Kingdom
HD3 3EA

Study participating centre**Birmingham Women's and Children's NHS Foundation Trust**

Steelhouse Lane
Birmingham
United Kingdom
B4 6NH

Study participating centre**Guy's and St Thomas' NHS Foundation Trust**

St Thomas' Hospital
Westminster Bridge Road,
London
United Kingdom
SE1 7EH

Study participating centre**University Hospitals of Leicester NHS Trust**

Leicester Royal Infirmary

Infirmery Square
Leicester
United Kingdom
LE1 5WW

Study participating centre
West Hertfordshire Teaching Hospitals NHS Trust
Trust Offices
Watford General Hospital
Vicarage Road
Watford
United Kingdom
WD18 0HB

Study participating centre
Imperial College Healthcare NHS Trust
The Bays
St Marys Hospital
South Wharf Road
London
United Kingdom
W2 1BL

Study participating centre
Milton Keynes University Hospital NHS Foundation Trust
Standing Way
Eaglestone
Milton Keynes
United Kingdom
MK6 5LD

Study participating centre
Manchester University NHS Foundation Trust
Cobbett House
Oxford Road
Manchester
United Kingdom
M13 9WL

Study participating centre

Bradford Teaching Hospitals NHS Foundation Trust

Bradford Royal Infirmary
Duckworth Lane
Bradford
United Kingdom
BD9 6RJ

Study participating centre

Sheffield Teaching Hospitals NHS Foundation Trust

Northern General Hospital
Herries Road
Sheffield
United Kingdom
S5 7AU

Study participating centre

Barts Health NHS Trust

The Royal London Hospital
80 Newark Street
London
United Kingdom
E1 2ES

Study participating centre

Liverpool Women's NHS Foundation Trust

Liverpool Womens Hospital
Crown Street
Liverpool
United Kingdom
L8 7SS

Study participating centre

Chelsea and Westminster Hospital NHS Foundation Trust

Chelsea & Westminster Hospital
369 Fulham Road
London
United Kingdom
SW10 9NH

Study participating centre

University Hospitals of Derby and Burton NHS Foundation Trust

Royal Derby Hospital
Uttoxeter Road
Derby
United Kingdom
DE22 3NE

Study participating centre**Croydon Health Services NHS Trust**

Croydon University Hospital
530 London Road
Thornton Heath
United Kingdom
CR7 7YE

Study participating centre**Oxford University Hospitals NHS Foundation Trust**

John Radcliffe Hospital
Headley Way
Headington
Oxford
United Kingdom
OX3 9DU

Study participating centre**Newham University Hospital NHS Trust**

Newham General Hospital
Glen Road
London
United Kingdom
E13 8SL

Study participating centre**West Middlesex University Hospital**

Twickenham Road
Isleworth
United Kingdom
TW7 6AF

Sponsor information

Organisation

University of East Anglia

Sponsor details

Norwich Research Park
Earlham Road
Norwich
England
United Kingdom
NR4 7TJ
+44 1603 289863
researchsponsor@uea.ac.uk

Sponsor type

University/education

Website

<https://www.uea.ac.uk/>

ROR

<https://ror.org/026k5mg93>

Funder(s)**Funder type**

Government

Funder Name

NIHR Evaluation, Trials and Studies Co-ordinating Centre (NETSCC)

Results and Publications**Publication and dissemination plan**

Planned publication in a high-impact peer-reviewed journal

Intention to publish date

31/01/2028

Individual participant data (IPD) sharing plan

The current data sharing plans for this study are unknown and will be available at a later date

IPD sharing plan summary

Data sharing statement to be made available at a later date